Trial Profile
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE DUO (Empagliflozin/Metformin, 5/500mg, 5/850mg, 5/1000mg, 12.5/500mg, 12.5/850mg, 12.5/1000mg) in Korean Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 May 2020 Status changed from active, no longer recruiting to completed.
- 24 Mar 2020 Planned primary completion date changed from 29 Feb 2020 to 30 Apr 2020.
- 24 Mar 2020 Status changed from recruiting to active, no longer recruiting.